Research programme: age-related macular degeneration therapies - Novelion Therapeutics
Latest Information Update: 30 Nov 2016
At a glance
- Originator QLT; Wilmer Eye Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
- 19 Dec 2006 Early research in Age-related macular degeneration in USA (unspecified route)